Genome & Company
http://genomecom.co.kr/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Genome & Company
Korean Biotech Roundup: String Of Positive R&D Developments Outweighs Some Setbacks
The South Korean biotech space has been marked by multiple positive R&D developments and pipeline and partnering progress in recent months, more than outweighing some other setbacks for the rapidly developing sector.
Korean Bioventure Financing Continues Downward Spiral In Q3
VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.
A Closer Look At The Korean Microbiome Therapeutic Landscape
Scrip takes an infographic look at various factors to keep an eye on in South Korea's rapidly developing microbiome therapy landscape this year, including emerging companies and their pipelines.
Finance Watch: Mega-Rounds Add Up To Another Record Year For Biopharma VC Funding
Private Company Edition: NVCA and Pitchbook data show pharma and biotech companies raised $37.8bn in venture capital in 2021, up 41% from the record $26.8bn total in 2020. Recent mega-rounds include $190m for Maze and $200m for Alumis, and Sound Bioventures raised a €110m fund.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice